Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Depatuxizumab mafodotin + Temozolomide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Depatuxizumab mafodotin | ABT-414|depatux-m | EGFR Antibody 60 | Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate comprising an EGFR-targeted antibody linked to an anti-microtubule drug, which delivers the cytotoxic agent to EGFR-expressing cells, potentially resulting in increased tumor cell death and decreased growth of EGFR-overexpressing tumors (PMID: 26846818, PMID: 29075855, PMID: 31747009, PMID: 32371586). | |
Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02573324 | Phase II | Temozolomide Depatuxizumab mafodotin + Temozolomide | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1) | Completed | USA | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 10 |